News

Technology News

Synta Launches New Small Molecule Conjugate Platform

Wednesday, September 11, 2013 5:16:00 AM PDT | VentureDeal
   Lexington, Massachusetts  --  Synta Pharmaceuticals (NASDAQ:SNTA) has announced the launch of a new small molecule platform.

Called the Hsp90-inhibitor Drug Conjugate Platform (HDC), the system promises to enable improved therapies for patients with cancer using small molecule modalities.

Synta says more than 350 HD-Conjugates have been developed to date using its platform.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1